CMO Speaks: Gene Therapy for SCD (Part 2)
Welcome to CMO Speaks, a blog featuring the voices of SCDAA’s clinical leadership team. This is part two of a three-part series on gene therapy for sickle cell disease. Part [...]
MARAC Statement: Health Insurance Coverage for MSD SCT
MARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-matched Sibling Donor (MSD HCT) Sept. 16, 2023 BACKGROUND Hematopoietic stem cell transplant for sickle [...]
MARAC Statement: Update About COVID
Sept. 16, 2023 - The worldwide pandemic of COVID-19 (SARS-CoV2) infections seem to have settled down, and we are now seeing waves of infections with new variants. As facemasks come [...]
SCDAA and MedicAlert Foundation Launch Pilot Program
Leading Sickle Cell Organization and MedicAlert Foundation Launch Pilot Program to Improve Emergency Care During Sickle Cell Pain Crises Non-profits partner to help people with sickle cell disease get faster, better [...]
Sickle Cell Awareness Month 2023 Events
All across the country, our member organizations are hosting exciting events for Sickle Cell Awareness Month this September. Check out the list below to find an event near you. Alabama [...]
Abstracts Accepted Until 11:59 p.m. PST
This morning, we were notified that some users experienced issues using our 2023 National Abstract Competition portal. This issue has been remedied. SCDAA is accepting abstract submissions until 11:59 p.m. [...]
MARAC Statement: Crizanlizumab (Adakveo)
July 7, 2023 - SCDAA’s Medical and Research Advisory Committee (MARAC) notes that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended on May 26, [...]
SCDAA Teams with MedicAlert Foundation
Sickle Cell Disease Association of America Teams with MedicAlert Foundation to Improve Emergency Outcomes During Sickle Cell Crises Nonprofits partner to help people with sickle cell disease get faster, better [...]
Afimmune joins the SCD C.A.R.E.S. Consortium
Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has been invited to join the Sickle Cell Disease Association of America’s (SCDAA) [...]
CMO Speaks: Gene Therapy for SCD (Part 1)
CMO Speaks is a blog featuring the voices of SCDAA’s clinical leadership team. Part 1 of our Gene Therapy series was written by Dr. Lewis Hsu and Dr. Sri Lakshmi [...]